ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 228 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.98 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $227,000 | -51.7% | 8,800 | 0.0% | 0.25% | -55.8% |
Q4 2020 | $470,000 | +95.8% | 8,800 | +51.2% | 0.57% | +69.5% |
Q3 2020 | $240,000 | -16.4% | 5,821 | -1.7% | 0.34% | -18.9% |
Q2 2020 | $287,000 | +14.8% | 5,921 | 0.0% | 0.42% | -2.6% |
Q1 2020 | $250,000 | -10.4% | 5,921 | -9.2% | 0.43% | +22.3% |
Q4 2019 | $279,000 | +31.6% | 6,521 | +10.5% | 0.35% | +21.1% |
Q3 2019 | $212,000 | -72.4% | 5,900 | -79.4% | 0.29% | -67.8% |
Q2 2019 | $767,000 | -9.9% | 28,700 | -9.5% | 0.90% | +24.4% |
Q1 2019 | $851,000 | +60.9% | 31,700 | -3.1% | 0.72% | +50.8% |
Q4 2018 | $529,000 | -47.5% | 32,700 | -32.6% | 0.48% | -41.1% |
Q3 2018 | $1,007,000 | +23.3% | 48,500 | -9.3% | 0.81% | +21.0% |
Q2 2018 | $817,000 | -47.3% | 53,500 | -22.5% | 0.67% | -49.2% |
Q1 2018 | $1,550,000 | -30.6% | 69,000 | -6.9% | 1.32% | -28.6% |
Q4 2017 | $2,233,000 | -19.2% | 74,150 | +1.1% | 1.85% | -20.1% |
Q3 2017 | $2,763,000 | +34.1% | 73,350 | -0.7% | 2.31% | +29.7% |
Q2 2017 | $2,060,000 | -17.4% | 73,850 | +1.8% | 1.78% | -19.1% |
Q1 2017 | $2,494,000 | +19.2% | 72,550 | 0.0% | 2.20% | +14.3% |
Q4 2016 | $2,092,000 | -5.4% | 72,550 | +4.3% | 1.93% | -7.4% |
Q3 2016 | $2,212,000 | -2.8% | 69,550 | -0.8% | 2.08% | -6.6% |
Q2 2016 | $2,275,000 | +10.3% | 70,100 | -5.0% | 2.23% | -7.1% |
Q1 2016 | $2,063,000 | -7.3% | 73,800 | +18.3% | 2.40% | -3.7% |
Q4 2015 | $2,225,000 | +41.5% | 62,400 | +31.2% | 2.49% | +43.7% |
Q3 2015 | $1,572,000 | -6.4% | 47,550 | +18.6% | 1.74% | +5.8% |
Q2 2015 | $1,679,000 | +156.3% | 40,100 | +99.5% | 1.64% | +168.0% |
Q1 2015 | $655,000 | +75.6% | 20,100 | +71.1% | 0.61% | +81.1% |
Q4 2014 | $373,000 | +5.7% | 11,750 | -17.5% | 0.34% | -4.2% |
Q3 2014 | $353,000 | +8.3% | 14,250 | -1.4% | 0.35% | +16.5% |
Q2 2014 | $326,000 | +11.3% | 14,450 | +19.9% | 0.30% | +7.4% |
Q1 2014 | $293,000 | -3.6% | 12,050 | -0.8% | 0.28% | -1.7% |
Q4 2013 | $304,000 | – | 12,150 | – | 0.29% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 647,833 | $26,723,000 | 11.32% |
GREAT POINT PARTNERS LLC | 1,921,563 | $79,264,000 | 7.13% |
Baker Brothers Advisors | 41,904,586 | $1,728,564,000 | 6.91% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 486,000 | $20,048,000 | 6.47% |
Palo Alto Investors LP | 1,832,300 | $75,582,000 | 4.15% |
Birchview Capital, LP | 204,000 | $8,416,000 | 2.81% |
SECTORAL ASSET MANAGEMENT INC | 556,514 | $22,956,000 | 1.97% |
Rock Springs Capital Management LP | 1,573,200 | $64,895,000 | 1.65% |
Riggs Asset Managment Co. Inc. | 17,470 | $2,025,000 | 0.85% |
PFM Health Sciences, LP | 421,087 | $17,370,000 | 0.80% |